[Skip to content]



The Cancer page covers both primary and secondary care, including screening, prevention, diagnosis and treatment. 

View the contents of the newsfeed below or subscribe using the link below. 

Search this subject


Latest News about Cancer

  • Exercise programme improves arm function and pain after breast cancer surgeryAn exercise programme improved women's recovery and upper limb movements after breast cancer surgery. Research found that the programme, introduced 7 to 10 days after surgery, was also safe and cost-effective to deliver. Many women develop problems in their shoulder, arm or hand (upper limb) after having surgery or radiotherapy for breast cancer. This can make everyday tasks, such as getting dressed, writing or lifting everyday objects, difficult. For some women, the problems can go on for years. Researchers, patients and clinical experts developed an exercise programme to help prevent upper limb problems after breast cancer surgery. The team tested the programme in women who had surgery to remove the cancer (but not to rebuild the breast - non-reconstructive surgery). Women in the study were at higher risk of developing problems because, for example, of the type of surgery they were due to have, or because they already had shoulder problems. The study found that women who received the exercise programme as well as information leaflets had fewer upper limb problems than those only given leaflets. Women in the exercise group felt reassured by the physiotherapist, had better quality of life, and reported less pain and arm symptoms than those only receiving leaflets. The team hopes that UK guidance will be updated to recommend the exercise programme after non-reconstructive breast cancer surgery. Training on the content and how to prescribe the programme is 2 External 0 0 0 available for free online false https://www.futurelearn.com/courses/prevention-of-shoulder-problems-prosper-programme false false%> via a structured course for healthcare professionals (for instance physiotherapists and breast cancer nurses). 27/09/2022
  • NHS expands home testing kits for bowel cancerAs part of an expansion of the programme, people aged 58 will now be eligible for the Faecal Immunochemical Tests for bowel cancer. This is the latest stage in the phased rollout for people aged 50 and over. Those newly eligible will receive an invitation letter. 17/08/2022
  • COVID-19 rapid guideline: delivery of systemic anticancer treatments [NG161], NICE (updated 11th August 2022)The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic. 11 August 2022: we reviewed the evidence and made new recommendations on shared decision-making. We withdrew some recommendations that are no longer relevant to the current stage of the pandemic. 11/08/2022
  • Primary care practice and cancer suspicion during the first three COVID-19 lockdowns in the UK: a qualitative study, BJGPStudy (17 interviews) notes some of changes will have been a positive step forward in modernisation of practice, but net impact of pandemic on detection of cancer has been negative, the full effect on stage, treatment intent, & survival may not be fully understood for some time. 10/08/2022
  • Recent cancer diagnosis or treatment lowers COVID-19 vaccine effectiveness, UK Covid Vaccine Research HubThis new study, published in the European Journal of Cancer, set out to evaluate the effectiveness of the third vaccine dose in over 360,000 people with cancer, compared to the general population, using data from Public Health England's national cancer dataset between December 2020 to December 2021. Overall, the researchers found that third vaccines doses were less effective in people with cancer than in the general population and concluded that many people with cancer remain at increased risk of infection, even after three doses. Lower vaccine effectiveness was found to be associated with: a cancer diagnosis in the previous 12 months lymphoma recent systemic anti-cancer therapy (SACT) or radiotherapy In the case of people with lymphoma, there was a marked reduction of vaccine effectiveness against breakthrough infection and severe disease. Overall, vaccine effectiveness for this cohort was found to be: 59.1% against breakthrough infections 62.8% against symptomatic infections 80.5% against hospitalisation from COVID-19 94.5% against death from COVID-19 02/08/2022
  • Bowel cancer resource guideTo help primary care services prepare for a possible increase in presentations and interest in bowel screening, this resource signposts health professionals to clinical guidance for the recognition, referral and management of suspected bowel cancer. 19/07/2022
  • JCVI updated statement on the COVID-19 vaccination programme for autumn 2022, DHSC (published 15th July 2022)JCVI has recommended a COVID booster to: all adults > 50 years; those aged 5-49 years in a clinical risk group, including pregnant women and household contacts of people with immunosuppression; carers aged 16-49 years; care home residents & staff & frontline health/social care staff. 19/07/2022
  • Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control studyStudy found overall vaccine effectiveness was 69.8% (95% CI 69.8–69.9) in the control population and 65.5% (65.1–65.9) in the cancer cohort. Vaccine effectiveness at 3–6 months was lower in the cancer cohort (47%, 46.3–47.6) than in the control population (61.4%, 61.4–61.5). 25/05/2022